Combinations of 5-HT2A inverse agonists and antagonists with antipsychotics

Details for Australian Patent Application No. 2008228833 (hide)

Owner Acadia Pharmaceuticals Inc.

Inventors Bahr, Daun; Brann, Mark; Furlano, David; Peters, Perry; Van Kammen, Daniel

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2008228833

PCT Pub. Number WO2008/116024

Priority 60/908,921 29.03.07 US; 60/895,735 19.03.07 US; 61/012,771 10.12.07 US; 61/026,092 04.02.08 US

Filing date 19 March 2008

Wipo publication date 25 September 2008

International Classifications

A61K 31/00 (2006.01)

A61K 31/4468 (2006.01) - having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl

A61K 31/4515 (2006.01) - having a butyrophenone group in position 1, e.g. haloperidol

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61K 31/554 (2006.01) - having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem

A61P 25/18 (2006.01) Drugs for disorders of the nervous system

Event Publications

12 November 2009 PCT application entered the National Phase

  PCT publication WO2008/116024 Priority application(s): WO2008/116024

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008228835-Automatically prescribing total budget for marketing and sales resources and allocation across spending categories

2008228823-Stable antibody formulations